RU2014101492A - Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак - Google Patents
Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак Download PDFInfo
- Publication number
- RU2014101492A RU2014101492A RU2014101492/10A RU2014101492A RU2014101492A RU 2014101492 A RU2014101492 A RU 2014101492A RU 2014101492/10 A RU2014101492/10 A RU 2014101492/10A RU 2014101492 A RU2014101492 A RU 2014101492A RU 2014101492 A RU2014101492 A RU 2014101492A
- Authority
- RU
- Russia
- Prior art keywords
- chokα
- cancer
- expression
- level
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382211.8 | 2011-06-20 | ||
| EP11382211 | 2011-06-20 | ||
| US201161507833P | 2011-07-14 | 2011-07-14 | |
| US61/507,833 | 2011-07-14 | ||
| EP11382294.4 | 2011-09-16 | ||
| EP11382294 | 2011-09-16 | ||
| PCT/EP2012/061790 WO2012175537A1 (en) | 2011-06-20 | 2012-06-20 | Method for predicting the clinical response to chemotherapy in a subject with cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014101492A true RU2014101492A (ru) | 2015-07-27 |
Family
ID=47422050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014101492/10A RU2014101492A (ru) | 2011-06-20 | 2012-06-20 | Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150004252A1 (enExample) |
| EP (1) | EP2721174A1 (enExample) |
| JP (1) | JP2014527397A (enExample) |
| KR (1) | KR20140047664A (enExample) |
| CN (1) | CN103687964A (enExample) |
| AU (1) | AU2012274156A1 (enExample) |
| BR (1) | BR112013032857A2 (enExample) |
| CA (1) | CA2840129A1 (enExample) |
| MX (1) | MX2013015286A (enExample) |
| RU (1) | RU2014101492A (enExample) |
| WO (1) | WO2012175537A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| US20170305861A1 (en) * | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
| ES2899114T3 (es) * | 2016-07-25 | 2022-03-10 | Nerviano Medical Sciences Srl | Análogos de purina y 3-deazapurina como inhibidores de colina cinasa |
| US11339447B2 (en) | 2017-03-29 | 2022-05-24 | Crown Bioscience, Inc. (Taicang) | System and method for determining Kareniticin sensitivity on cancer |
| CN107050668B (zh) * | 2017-06-09 | 2020-03-31 | 南京医科大学第一附属医院 | 基于云处理的放疗效果预测方法 |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| CN116859058B (zh) * | 2023-07-17 | 2026-08-04 | 上海中医药大学 | 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2237332B1 (es) | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
| PL1889920T3 (pl) * | 2005-04-13 | 2010-06-30 | Consejo Superior Investigacion | Sposób identyfikacji związków do terapii antynowotworowej in vitro |
| GB0519405D0 (en) * | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
| AU2009265121A1 (en) * | 2008-07-04 | 2010-01-07 | Traslational Cancer Drugs Pharma, S.L. | Methods for the treatment and diagnosis of cancer |
| EP3133170B1 (en) | 2008-09-10 | 2020-03-18 | Rutgers, the State University of New Jersey | Imaging individual mrna molecules using multiple singly labeled probes |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
-
2012
- 2012-06-20 AU AU2012274156A patent/AU2012274156A1/en not_active Abandoned
- 2012-06-20 CN CN201280035399.6A patent/CN103687964A/zh active Pending
- 2012-06-20 WO PCT/EP2012/061790 patent/WO2012175537A1/en not_active Ceased
- 2012-06-20 BR BR112013032857A patent/BR112013032857A2/pt not_active IP Right Cessation
- 2012-06-20 EP EP12730874.0A patent/EP2721174A1/en not_active Withdrawn
- 2012-06-20 KR KR1020147001560A patent/KR20140047664A/ko not_active Withdrawn
- 2012-06-20 US US14/128,369 patent/US20150004252A1/en not_active Abandoned
- 2012-06-20 MX MX2013015286A patent/MX2013015286A/es not_active Application Discontinuation
- 2012-06-20 CA CA2840129A patent/CA2840129A1/en not_active Abandoned
- 2012-06-20 RU RU2014101492/10A patent/RU2014101492A/ru not_active Application Discontinuation
- 2012-06-20 JP JP2014516320A patent/JP2014527397A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2721174A1 (en) | 2014-04-23 |
| US20150004252A1 (en) | 2015-01-01 |
| JP2014527397A (ja) | 2014-10-16 |
| KR20140047664A (ko) | 2014-04-22 |
| WO2012175537A1 (en) | 2012-12-27 |
| CN103687964A (zh) | 2014-03-26 |
| MX2013015286A (es) | 2014-09-25 |
| AU2012274156A1 (en) | 2014-01-23 |
| CA2840129A1 (en) | 2012-12-27 |
| BR112013032857A2 (pt) | 2017-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer | |
| He et al. | CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9 | |
| Nie et al. | Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer | |
| Koh et al. | Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy | |
| Shen et al. | miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway | |
| Raz et al. | Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer | |
| Ni et al. | Cortactin promotes colon cancer progression by regulating ERK pathway | |
| Kinny-Köster et al. | Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9 | |
| Liu et al. | TPX2 as a novel prognostic biomarker for hepatocellular carcinoma | |
| Pan et al. | Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer | |
| Zhang et al. | Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway | |
| Yun et al. | High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer | |
| Wang et al. | MicroRNA-10b is upregulated and has an invasive role in colorectal cancer through enhanced Rhoc expression | |
| US20180095070A1 (en) | Compositions and methods for prognosis and treatment of neoplasm | |
| Li et al. | S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma | |
| Zhu et al. | Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis | |
| Li et al. | Low expression of AIM2 combined with high expression of p-STAT3 is associated with poor prognosis in hypopharyngeal squamous cell carcinoma | |
| Shen et al. | MIR155HG knockdown inhibited the progression of cervical cancer by binding SRSF1 | |
| Jiang et al. | STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway Corrigendum in/10.3892/or. 2020.7855 | |
| Roh et al. | Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer | |
| Zhao et al. | Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma | |
| Lin et al. | Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer | |
| Zhang et al. | HSPA6, a novel prognostic and therapeutic biomarker, associated with Ming classification in gastric cancer | |
| Liu et al. | Elevated expression of Thoc1 is associated with aggressive phenotype and poor prognosis in colorectal cancer | |
| Yang et al. | Multifaceted bioinformatic analysis of m6A‐related ferroptosis and its link with gene signatures and tumour‐infiltrating immune cells in gliomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170911 |